Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma

Background and Objectives. The aim of the study was to determine systemic and fecal values of galectin-3 and pro- and anti-inflammatory cytokines in patients with CRC and the relationship with clinicopathological aspects. Methods. Concentrations of galectin-3, TNF-α, TGF-β, IL-10, and IL-1β were ana...

Full description

Saved in:
Bibliographic Details
Main Authors: Milan Jovanovic, Nevena Gajovic, Natasa Zdravkovic, Marina Jovanovic, Milena Jurisevic, Danilo Vojvodic, Veljko Maric, Aleksandar Arsenijevic, Ivan Jovanovic
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2018/8031328
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850161799488339968
author Milan Jovanovic
Nevena Gajovic
Natasa Zdravkovic
Marina Jovanovic
Milena Jurisevic
Danilo Vojvodic
Veljko Maric
Aleksandar Arsenijevic
Ivan Jovanovic
author_facet Milan Jovanovic
Nevena Gajovic
Natasa Zdravkovic
Marina Jovanovic
Milena Jurisevic
Danilo Vojvodic
Veljko Maric
Aleksandar Arsenijevic
Ivan Jovanovic
author_sort Milan Jovanovic
collection DOAJ
description Background and Objectives. The aim of the study was to determine systemic and fecal values of galectin-3 and pro- and anti-inflammatory cytokines in patients with CRC and the relationship with clinicopathological aspects. Methods. Concentrations of galectin-3, TNF-α, TGF-β, IL-10, and IL-1β were analyzed in samples of blood and stool of 60 patients with CRC. Results. Systemic concentration of TNF-α was significantly lower in patients with severe diseases (advanced TNM stage, nuclear grade, and poor histological differentiation) as in patients with more progressive CRC (lymph and blood vessel invasion, presence of metastasis). Fecal values of anti-inflammatory cytokines TGF-β and IL-10 were increased in patients with severe stadium of CRC. Fecal concentration of Gal-3 was enhanced in CRC patients with higher nuclear grade, poor tumor tissue differentiation, advanced TNM stage, and metastatic disease. Gal-3/TNF-α ratio in sera and feces had a higher trend in patients with severe and advanced diseases. Positive correlation between fecal Gal-3 and disease severity, tumor progression, and biomarkers AFP and CEA, respectively, was also observed. Conclusions. Predomination of Gal-3 in patients with advanced diseases may implicate on its role in limiting ongoing proinflammatory processes. The fecal values of Gal-3 can be used as a valuable marker for CRC severity and progression.
format Article
id doaj-art-fa0cd4225fee4b73a78d2b3d0b308964
institution OA Journals
issn 0962-9351
1466-1861
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-fa0cd4225fee4b73a78d2b3d0b3089642025-08-20T02:22:43ZengWileyMediators of Inflammation0962-93511466-18612018-01-01201810.1155/2018/80313288031328Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal CarcinomaMilan Jovanovic0Nevena Gajovic1Natasa Zdravkovic2Marina Jovanovic3Milena Jurisevic4Danilo Vojvodic5Veljko Maric6Aleksandar Arsenijevic7Ivan Jovanovic8Department of Abdominal Surgery, Military Medical Academy, Belgrade, SerbiaCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaDepartment of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaDepartment of Pharmacy, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaInstitute for Medical Research, Military Medical Academy, Belgrade, SerbiaDepartment of Surgery, Faculty of Medicine Foca, University of East Sarajevo, Sarajevo, Bosnia and HerzegovinaCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaCenter for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, SerbiaBackground and Objectives. The aim of the study was to determine systemic and fecal values of galectin-3 and pro- and anti-inflammatory cytokines in patients with CRC and the relationship with clinicopathological aspects. Methods. Concentrations of galectin-3, TNF-α, TGF-β, IL-10, and IL-1β were analyzed in samples of blood and stool of 60 patients with CRC. Results. Systemic concentration of TNF-α was significantly lower in patients with severe diseases (advanced TNM stage, nuclear grade, and poor histological differentiation) as in patients with more progressive CRC (lymph and blood vessel invasion, presence of metastasis). Fecal values of anti-inflammatory cytokines TGF-β and IL-10 were increased in patients with severe stadium of CRC. Fecal concentration of Gal-3 was enhanced in CRC patients with higher nuclear grade, poor tumor tissue differentiation, advanced TNM stage, and metastatic disease. Gal-3/TNF-α ratio in sera and feces had a higher trend in patients with severe and advanced diseases. Positive correlation between fecal Gal-3 and disease severity, tumor progression, and biomarkers AFP and CEA, respectively, was also observed. Conclusions. Predomination of Gal-3 in patients with advanced diseases may implicate on its role in limiting ongoing proinflammatory processes. The fecal values of Gal-3 can be used as a valuable marker for CRC severity and progression.http://dx.doi.org/10.1155/2018/8031328
spellingShingle Milan Jovanovic
Nevena Gajovic
Natasa Zdravkovic
Marina Jovanovic
Milena Jurisevic
Danilo Vojvodic
Veljko Maric
Aleksandar Arsenijevic
Ivan Jovanovic
Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
Mediators of Inflammation
title Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
title_full Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
title_fullStr Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
title_full_unstemmed Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
title_short Fecal Galectin-3: A New Promising Biomarker for Severity and Progression of Colorectal Carcinoma
title_sort fecal galectin 3 a new promising biomarker for severity and progression of colorectal carcinoma
url http://dx.doi.org/10.1155/2018/8031328
work_keys_str_mv AT milanjovanovic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT nevenagajovic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT natasazdravkovic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT marinajovanovic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT milenajurisevic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT danilovojvodic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT veljkomaric fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT aleksandararsenijevic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma
AT ivanjovanovic fecalgalectin3anewpromisingbiomarkerforseverityandprogressionofcolorectalcarcinoma